The tumour microenvironment comprises complex cellular compositions and interactions between cancer, immune, and stromal components which all play crucial roles in cancer. Various computational approaches have been developed during the last decade that estimate the relative abundance of different cell types in an unbiased manner using bulk tumour RNA data. However, a comparison that objectively evaluates the performance of these approaches against one another has not been 30 conducted. Here we benchmarked six widely used tools and gene sets: Bindea et al. gene sets, Davoli et al. gene sets, CIBERSORT, MCP-counter, TIMER, and xCell. We also introduce Consensus TME , a consensus approach that uses the union of genes that the six tools used for cell estimation, and corrects for tumour type specificity. We benchmarked the seven tools using TCGA DNA-derived purity scores (33 tumour types), methylation-derived leukocyte scores (30 tumour types), and H&E deep 35 learning derived lymphocyte counts (13 tumour types), and individual benchmark data sets (PBMCs and 2 tumour types). Although none of the seven tools outperformed others in every benchmark, Consensus TME ranked consistently well in all cancer-related benchmarks making it the top performing method overall. Computational methods that provide robust and accurate estimates of noncancerous cell populations in the tumour microenvironment from tumour bulk expression data are 40 important tools that can advance our understanding of tumour, immune, and stroma interactions, with potential clinical application if high accuracy estimates are achieved.
INTRODUCTION
The tumour microenvironment (TME) plays an active role in in tumour initiation, progression, metastasis, and treatment response. Thus, studying the TME is a central paradigm of cancer research.
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However, a great variety of stromal and immune cell types populate tumour tissues, and the complex interactions between these different components of the tumour microenvironment is still unclear.
Traditionally, cells from the TME have been quantified using immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry, and more recently using cytometry by time of flight (CyTOF). These methods, although accurate, are laborious, low throughput and require pre-selected 50 cellular markers, making their application in large number of samples and measurements challenging.
Thus, their systematic application for comprehensively investigating the various different cell types in the TME in an unbiased manner is limited. Single cell RNA sequencing (scRNA-seq) has begun to fill this gap, however scRNA-seq is still too expensive to apply on large number of samples such as The Cancer Genome Atlas (TCGA) which consists of thousands of genomically profiled tumour samples 55 which are also clinically well annotated. The study of the different cell subpopulations of the TME in TCGA has become an important goal, but also an important challenge for bioinformatics, since cell type information identity is mixed in bulk tumour transcriptomics data.
Estimation of non-cancerous cell proportions from bulk tumour samples has been performed using 60 genomics data such as whole-exome sequencing, microarrays, RNA-seq, or DNA methylation data.
During the last decade, multiple computational approaches have been developed intending to quantitatively or semi-quantitatively calculate distinct TME cell type population estimates 1 . A variety of statistical frameworks and algorithmic procedures have been employed, and each method has used different benchmark datasets 1 . In general, two different algorithmic classes into which most methods 65 can be classified are: deconvolution algorithms and gene set enrichment-based methods. Importantly, both classes rely on cell type specific markers that are selected according to prior knowledge. The deconvolution algorithms use linear combinations of the expression values of the cell-specific genes, while gene set enrichment-based methods rank the genes of a mixture sample and compute enrichment scores as a function of the ranked selected genes. This is a challenging task, particularly 70 to reliably estimate lowly abundant cell populations, and also because the gene sets are not unique to any particular cell type. Thus, there is not a straightforward solution for accurate TME cell estimation, and one of the problems in the field is that each method has claimed to outperform others in their own benchmarking experiments 2,3 . Thus, the need for independent and more comprehensive benchmarks has been pointed out 4 . Here, we developed a consensus approach (Consensus TME ) that 75 leverages current state-of-the-art knowledge by compiling common cell type specific gene sets used by six published TME cell estimation methods. We performed pan-cancer benchmarks using publicly available bulk RNA sequencing data from TCGA and side-by-side comparisons using the methods' independent benchmarks. The Consensus TME approach is evolvable by design allowing new methods and algorithms to be incorporated and their performance compared with continuously updated 80 benchmark data sets. Overall, the consensus approach will lead towards robust and improved tools for the estimation of cell type quantities using bulk expression data of human tumour samples.
RESULTS

Consensus tumour type specific superset of tumour microenvironment cell populations
Following the generation of large data sets of tumour genomic profiles such as TCGA and ICGC, various 85 computational tools assessing TME cell populations have been developed, each using different algorithms, gene markers, and validation benchmarks. To build on the knowledge of cell type specific gene sets represented in the diversity of these methods, we sought an integrative strategy that incorporates knowledge from existing tools. Consensus TME integrates cell type specific gene markers from independent cell estimation methods and uses single sample gene set enrichment analysis 90 (ssGSEA) to compute TME cell type and tumour specific enrichment scores from bulk expression data ( Figure 1A ). The ssGSEA approach was selected because its treats microarray and RNAseq values in the same way, since it is based on the ranked genes rather than the actual values. To generate Consensus TME gene sets, we selected six widely used cell estimation methods: CIBERSORT 5 , TIMER 6 , MCP-counter 7 , xCell 8 , and the gene sets generated and use in Bindea et al. 9 and Davoli et al. 10 here 95 called "Bindea" and "Davoli" supersets, respectively. In brief, we first selected cells that are estimated by at least two methods. Second, we generated a gene set for each cell type by using the union of genes used by the methods to estimate that cell type, and removed genes that correlate (rho > -0.2) with tumour purity 6 (see Methods). Therefore, Consensus TME aggregates cell type specific genes that have been independently considered relevant by different methods, and estimates their abundance 100 in a tumour type specific manner.
Pan-cancer leukocyte and lymphocyte benchmarks
To benchmark the different methods in an objective and systematic manner, we used publicly available data from between 13 and 32 tumour types comprising 9,142 tumour samples in total. First, to evaluate the ability of each method to capture the overall amount of immune component in the 105 TME we correlated DNA-based tumour purity scores 11, 12 with immune scores inferred by the different methods either natively, or derived when not generated by default (see Methods). Since tumour purity does not account only for immune cell infiltration but also for other stromal cells (e.g.
fibroblasts and endothelial cells), this would affect the correlation of methods that only estimate immune cells. Therefore, we inferred stromal non-immune related content of all samples using 110 ESTIMATE 13 and added this value to all methods' immune scores to create a purity score. We found that all six methods and Consensus TME perform very similar to each other, with CIBERSORT, Consensus TME , and Davoli as the top 3 pan-cancer negative correlations ( Figure 1B ). Across tumour types, the different methods performed similar and very few correlations were not statistically significant. However, cancer-specific performance of methods was observed with methods 115 consistently performing well in cancers such as ovarian cancer (OV) and glioblastoma multiforme (GBM) while showing lower performance in pancreatic adenocarcinoma (PAAD). Variation in performance was largely independent of cancer cellularity, mutation load, leukocyte fraction, and sample size for any of the methods.
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We further evaluated the performance of the methods by using leukocyte fractions derived from methylation data for 30 tumour types 12 . For the initial analysis we assessed performance by correlating levels of CD8 + T cells, an important prognostic cell type, with leukocyte fraction. The best performing methods for this analysis were Consensus TME , Davoli and MCP-Counter. To extend this analysis to account for accuracy across multiple cell types we fitted multiple linear regression models 125 using the leukocyte fraction as a response variable and only cell type estimates in the category of being leukocytes as explanatory variables for each method. Since different methods estimate different number of leukocytes, the coefficient of determination can be artificially increased by the number of variables in a model (i.e. overfitting). Thus, to more appropriately compare the models in an unbiased way we used adjusted coefficients of determination (R 2 ), the Akaike information criterion (AIC), and 130 Bayesian information criterion (BIC) for model comparison. These penalise model complexity (i.e. number of cell types used in the models) to varying degrees. When comparing the R 2 of the different models, the best performing methods were Bindea, Consensus TME , and Davoli ( Figure 1D ). Similarly, AIC and BIC scores showed that Consensus TME , Davoli, and Bindea models perform better than the other methods (models with lower AIC and BIC values are preferred). We also implemented multiple 135 linear regression analysis using tumour-infiltrating lymphocyte counts derived from digitised H&Estained images analysed through a deep-learning convolutional neural network approach 14 . Although low coefficient of determination values was obtained across methods, likely due to the very difficult task of computationally detect leukocytes on H&E images, the methods that obtained a higher coefficient of determination were Bindea, CIBERSORT, and Consensus TME , while the lowest AIC and BIC 140 values were obtained by Consensus TME , Davoli, and TIMER ( Figure 1E ). Together, these broad pancancer benchmarks show a variation in the performance of the different methods when compared to each other, and no single method consistently outperforms the others. The cancer specific performance observed in these experiments was also an important finding that should be taken into account when considering the appropriateness of using these tools. 
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Again, MCP-counter, CIBERSORT, and xCELL were the methods that showed best performance in these PBMC benchmarks, however many cell types did not reach statistical significance ( Figure 2B ).
Finally, we used cancer-related benchmarks from TIMER 6 and MCP-counter 7 . For TIMER's benchmark, 404 TCGA bladder cancer samples were analysed by a pathologist who categorised them as low, 180 medium, or high according to their neutrophil counts using H&E stained slides. Then performance was assessed by measuring the significance of difference between the computational estimates of samples in each category. Here, Consensus TME , Bindea, and TIMER obtained the best separation between categories, but only Consensus TME and Bindea separated significantly the three categories after multiple test correction ( Figure 2C) Figure 2D ). Consensus TME , MCPcounter, and Davoli methods provided the best correlations, with Consensus TME outperforming on the 190 three cell types.
When observing the rank of methods across all benchmarking experiments (Supplementary figure S1) no one method was shown to consistently outperform all others. However, the integrative Consensus TME approach was in the top three for all cancer-based benchmarks and achieved the lowest 195 mean rank of all methods. 
DISCUSSION
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With the recent generation of large publicly available molecular profiling of cancer samples, a variety of computational tools for analysis of cell components of the TME have been generated. In principle, the method of choice should be based on performance, however popularity and ease of use can also be reasons behind the method researchers select 4 . In the case of TME cell estimation from bulk expression data, this problem is magnified by the lack of objective and independent benchmark 215 analyses, since most methods use their own benchmarks which may introduce biases and reliance on one type of data. Here we performed an unbiased and objective benchmarking exercise comparing six of the most widely used and recent tools, and also developed Consensus TME : a gene set enrichmentbased method that integrates cells and genes from these six different tools in order to generate a consensus gene superset for each cell type that is tumour type specific.
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We performed pan-cancer benchmarks using orthogonal data types generated for TCGA samples.
While DNA-derived tumour purity scores correlated negatively with RNA-derived TME estimations in all methods, leukocyte methylation scores showed some distinction across methods, and a lack of correlation in some cases. Also, different tumour types showed varying levels of correlation with leukocyte estimations, which could be due to the leukocyte methylation signature model. This was generated by comparing pure leukocyte cells and normal tissue methylation patterns with tumour type specific methylation patterns 12 , and tumour infiltrating leukocytes may have different methylation patterns. Furthermore, lymphocyte deep learning H&E quantifications provided a lower association with lymphocyte RNA-derived estimations, an observation that has been reported before 230 and considered to be in part due to the RNA-derived estimates reflect more cell counts, while spatial image-derived estimates reflect the fraction of lymphocytes per area 14, 16 . Thus, this benchmark is inconclusive due to the uncertainty of both RNA-derived and imaged-based derived lymphocyte estimates, but it was included to achieve more comprehensive and orthogonal benchmarks.
Moreover, similar results to the leukocyte methylation benchmark were detected. Side-by-side 235 benchmarking on the different methods data sets showed that PBMC-based benchmarks present a low number of significant correlations across methods, and due to the diversity of cells tested and estimated by the different methods obtaining a concluding result out of these benchmarks is challenging. Moreover, for the application of TME cell estimation using bulk RNA tumour data, PBMC benchmarks may not be very informative as the transcriptomes of the circulating and tumour 240 infiltrating immune cells are different. In contrast, both BLCA and COADREAD benchmarks on neutrophils, CD3 + , CD68 + , and CD8 + cells showed significant associations for some tools, particularly Consensus TME . These benchmarks showed that no independent method consistently outperforms other methods. Nevertheless, overall Consensus TME ranked among the top three best performing methods in all cancer-relates benchmarks. Lastly, Consensus TME is an evolvable method by conception, 245 which means that other genes used by new methods can be added to existing supersets and tested with already established benchmarks, thus potentially improving its performance as new methods and gene sets are developed.
Contact for Reagent and Resource Sharing
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Martin L. Miller (martin.miller@cruk.cam.ac.uk).
Quantification and Statistical Analysis 255
Single-sample gene set enrichment analysis
Single-sample gene set enrichment analysis 17 , a modification of standard GSEA 18 , was performed on RNA measurements for each sample using the GSVA package version 1.28.0 19 in R version 3.5.0 with parameters: method = 'ssgsea', and tau = 0.25. Normalized enrichment scores (NES) were generated for the hallmark gene sets 20 , immune and stromal signatures 13 , TME cell gene sets obtained from 260 previous publications 9,10 , as well as the Consensus TME gene sets ( Figure S3A ). Hallmark gene sets were obtained from MSigDB database version 6.1 20 .
Consensus TME
To generate the Consensus TME gene sets we identified cell types that were deconvoluted by at least 2 different methods, 18 in total. We then combined the gene sets that the different methods considered 265 for the deconvolution of such cell types. To include genes used in CIBERSORT, we first filtered out genes whose expression value was below 1.96 standard deviations of the mean for each cell type. In addition, we collapsed activated and resting states for corresponding cell types. The union of genes was the filtered to exclude genes whose expression has a Pearson's correlation coefficient > -0.2 and a p-value > 0.05 when correlated with tumour purity; as defined by TIMER 6 . Finally, ssGSEA was employed to calculate NES for each cell type as described above. General immune scores for each tumour types were generated by combining the genes of the different immune cells into one gene set.
Comparison statistical metrics
Concordance between computational estimates and ground truth values was measured using either 275 Kendall's rank correlation coefficient or the multiple linear regression goodness of fit metrics: adjusted R-squared, Akaike information criterion (AIC), and Bayesian information criterion (BIC). AIC and BIC zscores values were calculated to incorporate different tumour types in the comparisons since AIC and BIC values are unitless. Differences between groups of variables were identified using one-way ANOVA with Tukey honest significant differences post-hoc tests. All statistical tests were adjusted for multiple 280 testing using the Benjamini-Hochberg procedure to control for false discovery rate (FDR).
TCGA immune estimations
RNA-sequencing (RNA-seq) data was collected from cBioPortal 21 . Batch normalisation had been applied and gene expression values calculated using the "RSEM" pipeline 22 . Four existing TME cell estimation methods and two published gene sets were used alongside Consensus TME to produce 285 relative abundances of immune cell types per sample across 32 tumour types. For each method, a general immune score was also derived if it was not already provided, representing the total level of immune cell infiltration in each tumour sample.
TME cell deconvolution methods
Cell deconvolution methods were used to estimate levels of non-cancerous cells in the TME. The The "xCell" R package (version 1.12) was used to generate immune estimates for the xCell method 8 .
A general immune estimation score is already provided by xCell.
MCP-counter
Estimations for the MCP-counter method were produced using the "MCPcounter" R package (version 305 1.1.0) 7 . Immune scores for this method were produced in a similar manner as the ssGSEA methods by creating a union of signature genes for each of the cell types. The "MCPcounter.estimate" function was used to allow for the new signature.
CIBERSORT
310
CIBERSORT estimations were produced using the R source code, provided on request from the web resource 5 . CIBERSORT was run in "Absolute mode" (under beta development) using 100 permutations and quantile normalisation disabled as recommended for RNA-seq data. Absolute scores representing the "overall immune content" is produced natively by the algorithm in absolute mode.
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TIMER TIMER estimations were produced using R source code, available from the web resource 6 . Immune scores for TIMER were produced as a sum of the coefficients for each cell type.
Purity score benchmark
Pan-cancer purity scores were downloaded from the NIH Genomic Data Commons (https://gdc.cancer.gov/about-data/publications/PanCan-CellOfOrigin) 12 . Purity scores were generated using ABSOLUTE 11 which uses copy number, variant allele frequency, and tumour specific karyotype data to calculate the cancer fraction of a tumour samples. To benchmark the immune 325 estimation methodologies using purity of samples the immune scores were added to an independent stromal score; calculated through the use of ESTIMATE (version 1.0.13) 13 
Somatic single nucleotide mutation data
Somatic single nucleotide mutation data was downloaded from the Broad Institute GDAC Firehose 23 . 
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H&E deep learning lymphocyte fractions benchmark
360
Independent methods side-by-side benchmarks
The benchmarking validation analyses for each of the methods were replicated, where possible, to match the parameters used in the original publications. Of the six methods there were four benchmarking datasets available; either online or provided by the authors. Each of the datasets contained samples with bulk gene expression values along with matched "ground truth" values. The
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CIBERSORT benchmarking dataset, provided by the authors on request 5 , consisted of flow cytometry values of different immune cell types from PBMC samples. The xCell benchmarking datasets, SDY311 and SDY420, were publicly available for download from ImmPort 15 , and the validation data consisted of matching CyTOF quantification of immune cells from PBMC samples. The MCP-counter publication used gene expression profiles from GEO (accession number GSE39582) and IHC counts of CD3 + , CD8 + , slides from TCGA Bladder urothelial carcinoma (BLCA) study. Pathological estimations of these slides were carried out to categorise each sample into one of three categorical levels for neutrophil abundance: "Low", "Medium" or "High"; estimations are available from the TIMER online resource 6 .
For all benchmarking experiments, except TIMER, concordance was measured using correlation 375 between "ground truth" values and the immune estimations of each method. Due to the variation in the degree of specificity to which cell subsets were defined, summations of subsets were required to allow accurate comparisons in some cases. For the TIMER benchmark, the in-silico neutrophil estimations for each method were grouped by low, medium and high pathological estimation, then compared through ANOVA with Tukey post hoc. Figure S1 : Summary of benchmarking experiments with Consensus TME highlighted. Line plot for rank of method in each benchmark. Mean rank in final column. As Davoli the method does not allow for prediction of neutrophils 395 it was given the lowest rank for the TIMER benchmark.
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